Real World Use of Tocilizumab Biosimilar studY

Persistence of tocilizumab treatment 6 months after treatment start with Tyenne, a tocilizumab biosimilar

The goal of this non interventional study is to evaluate the use of Tyenne, a tocilizumab
 biosimilar, in a real world setting in Rheumatoid Arthritis (RA) patients over a period of 12
 months.
 
 The main questions it aims to answer are:
 
 - What is the patients' persistence on Tyenne (patient's ability to continue the treatment
 for the prescribed duration), 6 months after treatment start?
 
 - What is the patients' persistence on Tyenne (patient's ability to continue the treatment
 for the prescribed duration), 12 months after treatment start?
 
 The decision of prescribing Tyenne will be done by the physician independently, prior to
 patient enrolment in the study. Enrolled patients will be followed for 12 months following
 Tyenne treatment start, or until they permanently discontinue Tyenne.
 
 There will be one baseline visit and three follow-up visits at approximately 3, 6 and 12
 months after Tyenne treatment initiation. All follow-up visits will be conducted according to
 the physician current clinical practice and are not imposed due to this protocol.